To identify the common pathway or pathways that drive CRC growth in these patient-derived cell lines, we next screened CRC057, CRC119 and CRC240 with specific inhibitors of ponatinib’s targets, including ABL, FGFR, PDGFR, SRC and VEGFR. Here, PDGFRB is linked to colorectal carcinoma.